Human babesiosis

R Waked, PJ Krause - Infectious Disease Clinics, 2022 - id.theclinics.com
Babesiosis is an infection caused by intraerythrocytic protozoa of the genus Babesia.
Different species of Babesia infect different vertebrate hosts, but human disease has been …

Relapsing Babesiosis With Molecular Evidence of Resistance to Certain Antimicrobials Commonly Used to Treat Babesia microti Infections

LA Marcos, GP Wormser - Open Forum Infectious Diseases, 2023 - academic.oup.com
Human babesiosis cases are emerging with an increased incidence and a wider geographic
range worldwide. Relapsing babesiosis cases are becoming more frequently encountered …

[HTML][HTML] Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities

SS Hu, Z Batool, X Zheng, Y Yang, A Ullah… - Journal of …, 2024 - Elsevier
Protozoan infections (eg, malaria, trypanosomiasis, and toxoplasmosis) pose a considerable
global burden on public health and socioeconomic problems, leading to high rates of …

Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment …

RI Horowitz, J Fallon, PR Freeman - Microorganisms, 2023 - mdpi.com
Twenty-five patients with relapsing and remitting Borreliosis, Babesiosis, and bartonellosis
despite extended anti-infective therapy were prescribed double-dose dapsone combination …

[HTML][HTML] Efficacy of clofazimine and nitazoxanide combination in treating intestinal cryptosporidiosis and enhancing intestinal cellular regeneration in …

M Esmat, AA Abdel-Aal, MA Shalaby, M Badawi… - Food and Waterborne …, 2022 - Elsevier
Cryptosporidium is a widely distributed food and water-borne enteric protozoan that affects a
wide range of vertebrates, resulting in life-threatening consequences, particularly in …

Efficacy of the Antimalarial MMV390048 against Babesia Infection Reveals Phosphatidylinositol 4-Kinase as a Druggable Target for Babesiosis

S Ji, EM Galon, MA Rizk, Y Yi, I Zafar, H Li… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
The present study aimed to evaluate the anti-Babesia effect of MMV390048, a drug that
inhibits Plasmodium by targeting the phosphatidylinositol 4-kinase (PI4K). The half inhibitory …

Babesiosis in immunosuppressed hosts: pathogenesis, diagnosis and management

HM Heller - Current Opinion in Infectious Diseases, 2024 - journals.lww.com
Babesiosis is likely to become a more frequent infectious complication in
immunosuppressed hosts as the areas of endemicity expand. Reduced efficacy of standard …

Clofazimine for babesiosis: preclinical data support a clinical trial

E Vannier, JA Gelfand - The Journal of Infectious Diseases, 2022 - academic.oup.com
Forty years have passed since a pediatric case of babesiosis set the stage for a therapeutic
approach to this parasitic disease [1]. The infant, born in the 30th week of gestation, had …

Phosphatidylinositol 4-kinase is a viable target for the radical cure of Babesia microti infection in immunocompromised hosts

S Ji, EM Galon, MM Amer, I Zafar… - Frontiers in Cellular …, 2022 - frontiersin.org
Human babesiosis is a global emerging tick-borne disease caused by infection with intra-
erythrocytic parasites of the genus Babesia. With the rise in human babesiosis cases, the …

[PDF][PDF] Discovery and evaluating new drugs for babesiosis treatment

S JI - 2023 - obihiro.repo.nii.ac.jp
Babesia. The most notable species include Babesia bigemina, B. divergens, and B. bovis for
bovine, B. caballi for equine, B. canis and B. gibsoni for canine, and B. microti and B …